CanSino Biologics proposes governance refresh, board changes

CanSino Biologics Inc. announced resolutions from its October 27, 2025, board meeting, including the proposed cancellation of its board of supervisors. This change, subject to shareholder approval at an extraordinary general meeting (EGM), will transfer the supervisors' powers and functions to the board’s audit committee. This necessitates amendments to the articles of association and rules of procedures to align with the Company Law of the People's Republic of China. The company also plans to amend various corporate governance rules to further enhance standards and protect shareholder interests.

Concurrently, independent non-executive directors Shuifa Gui and Jianzhong Liu have tendered their resignations due to the expiry of their six-year terms. They will continue to serve until new appointments are made at the EGM. The board has nominated Man Cho and Xuefeng Ji as new independent non-executive director candidates. Cho, born in May 1961, has extensive experience in the pharmaceutical sector, while Ji, born in May 1978, brings over 10 years of legal expertise.

Upon approval at the EGM, Cho and Ji will receive an annual director’s fee of RMB300,000 (pre-tax) each, in line with the remuneration plan approved on February 21, 2024. A circular detailing these proposed changes will be dispatched to shareholders.